S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$46.73
+0.84 (+1.83%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$45.00
▼
$46.75
50-Day Range
$43.80
▼
$50.01
52-Week Range
$42.01
▼
$66.00
Volume
459,375 shs
Average Volume
708,224 shs
Market Capitalization
$4.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.40

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
48.5% Upside
$69.40 Price Target
Short Interest
Bearish
3.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$11.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.43) to ($1.14) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

326th out of 989 stocks

Pharmaceutical Preparations Industry

143rd out of 480 stocks

See Top Rated MarketRank™ Stocks Here

ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

March 19, 2023 | americanbankingnews.com
Comparing Intra-Cellular Therapies (NASDAQ:ITCI) & Pacira BioSciences (NASDAQ:PCRX)
March 16, 2023 | americanbankingnews.com
Suresh K. Durgam Sells 7,344 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 14, 2023 | americanbankingnews.com
Insider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CFO Sells 5,582 Shares of Stock
March 14, 2023 | americanbankingnews.com
Lawrence J. Hineline Sells 15,663 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock
March 14, 2023 | americanbankingnews.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $370,557.00 in Stock
March 14, 2023 | americanbankingnews.com
Sharon Mates Sells 41,770 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock
March 14, 2023 | americanbankingnews.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 20,565 Shares
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 14, 2023 | americanbankingnews.com
Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) PT at $69.40
March 7, 2023 | msn.com
Intra-Cellular Therapies's Return On Capital Employed Overview
March 3, 2023 | benzinga.com
Intra-Cellular Therapies Stock (NASDAQ:ITCI), Analyst Ratings, Price Targets, Predictions
March 3, 2023 | finance.yahoo.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2022 Earnings Call Transcript
March 2, 2023 | finance.yahoo.com
Intra-Cellular Therapies Full Year 2022 Earnings: EPS Beats Expectations
March 1, 2023 | finanznachrichten.de
Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
February 28, 2023 | msn.com
Earnings Outlook For Intra-Cellular Therapies
February 24, 2023 | benzinga.com
Intra-Cellular Therapies Stock (NASDAQ:ITCI), Quotes and News Summary
February 14, 2023 | finance.yahoo.com
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
February 8, 2023 | finance.yahoo.com
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
January 24, 2023 | reuters.com
ITCI.PH - | Stock Price & Latest News | Reuters
January 8, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), 2seventy bio (TSVT) and Privia Health Group (PRVA)
January 3, 2023 | finance.yahoo.com
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 | thestreet.com
Intra-Cellular Therapies (ITCI) Stock Climbs After Pricing 6.9 Million Share Offering
December 20, 2022 | finance.yahoo.com
Is Intra-Cellular Therapies (ITCI) a Worthy Investment Option?
December 18, 2022 | seekingalpha.com
Intra-Cellular: Hitting A Growth Inflection (Rating Upgrade)
December 14, 2022 | finance.yahoo.com
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
December 12, 2022 | finance.yahoo.com
Should You Retain Your Holdings in Intra-Cellular Therapies (ITCI)?
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
3/01/2023
Today
3/24/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
CUSIP
N/A
CIK
1567514
Web
www.intracellulartherapies.com
Phone
(464) 440-9333
Fax
646-440-9334
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$69.40
High Stock Price Forecast
$93.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+53.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-256,260,000.00
Net Margins
-102.37%
Pretax Margin
-102.37%
Return on Equity
-35.88%
Return on Assets
-31.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.87
Quick Ratio
8.58

Sales & Book Value

Annual Sales
$250.31 million
Price / Sales
17.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.93 per share
Price / Book
6.52

Miscellaneous

Outstanding Shares
95,280,000
Free Float
91,755,000
Market Cap
$4.30 billion
Optionable
Optionable
Beta
1.13

Key Executives

  • Sharon MatesSharon Mates
    Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline
    Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis
    Chief Scientific Officer & Senior Vice President
  • Suresh DurgamSuresh Durgam
    Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy
    Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

9 brokerages have issued 12-month price targets for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $49.00 to $93.00. On average, they expect the company's share price to reach $69.40 in the next year. This suggests a possible upside of 53.6% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the start of the year. Since then, ITCI shares have decreased by 14.6% and is now trading at $45.17.
View the best growth stocks for 2023 here.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,310,000 shares, an increase of 37.9% from the February 13th total of 2,400,000 shares. Based on an average trading volume of 659,000 shares, the days-to-cover ratio is currently 5.0 days.
View Intra-Cellular Therapies' Short Interest.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ITCI earnings forecast.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Wednesday, March, 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $87.87 million during the quarter, compared to analysts' expectations of $86.97 million. Intra-Cellular Therapies had a negative net margin of 102.37% and a negative trailing twelve-month return on equity of 35.88%. Intra-Cellular Therapies's revenue for the quarter was up 242.3% compared to the same quarter last year. During the same quarter last year, the company earned ($1.05) EPS.

What ETFs hold Intra-Cellular Therapies' stock?

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include Psyk Etf (PSYK), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (2.13%), Franklin Resources Inc. (1.89%), Geode Capital Management LLC (1.76%), JPMorgan Chase & Co. (1.58%), GW&K Investment Management LLC (1.53%) and Millennium Management LLC (1.47%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $45.17.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $4.30 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 3/24/2023 by MarketBeat.com Staff